Advanced search
Publication Cover
Clinical Ophthalmology Volume 17, 2023 - Issue
Submit an article Journal homepage
134
Views
0
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Treatment of Diabetic Macular Edema or Macular Edema Following Retinal Vein Occlusion Based on Repeated Injection of the Dexamethasone Intravitreal Implant: A Retrospective Real-World Analysis

Francis WB SandersDepartment of Ophthalmology, Singleton Hospital, Swansea, UKCorrespondence[email protected]
View further author information
,
Rhys Dumont JonesDepartment of Ophthalmology, Singleton Hospital, Swansea, UKView further author information
,
David R JonesDepartment of Ophthalmology, Singleton Hospital, Swansea, UKView further author information
,
Sean V PhillipsDepartment of Ophthalmology, Singleton Hospital, Swansea, UKView further author information
&
Gwyn S WilliamsDepartment of Ophthalmology, Singleton Hospital, Swansea, UKView further author information
Pages 3177-3187 | Received 15 Jul 2023, Accepted 11 Oct 2023, Published online: 24 Oct 2023

References

  • Haller JA, Bandello F, Belfort JR, et al. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology. 2010;117:1134–1146. doi:10.1016/j.ophtha.2010.03.032
  • Ozurdex. Summary of product characteristics; 2022. Available from: www.medicines.org.uk/emc/product/5654/smpc. Accessed December 20, 2022.
  • Boyer DS, Yoon YH, Belfort JR, et al. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology. 2014;121:1904–1914. doi:10.1016/j.ophtha.2014.04.024
  • Danis RP, Sadda S, Li XY, et al. Anatomical effects of dexamethasone intravitreal implant in diabetic macular oedema: a pooled analysis of 3-year Phase III trials. Br J Ophthalmol. 2016;100:796–801. doi:10.1136/bjophthalmol-2015-306823
  • Maturi RK, Pollack A, Uy HS, et al. Intraocular pressure in patients with diabetic macular edema treated with dexamethasone intravitreal implant in the 3-year MEAD study. Retina. 2016;36:1143–1152. doi:10.1097/IAE.0000000000001004
  • Haller JA, Bandello F, Belfort JR, et al. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology. 2011;118:2453–2460. doi:10.1016/j.ophtha.2011.05.014
  • Chawan-Saad J, Wu M, Wu A, Wu L. Corticosteroids for diabetic macular edema. Taiwan J Ophthalmol. 2019;9:233–242. doi:10.4103/tjo.tjo_68_19
  • Schmidt-Erfurth U, Garcia-Arumi J, Gerendas BS, et al. Guidelines for the management of retinal vein occlusion by the European Society of Retina Specialists (EURETINA). Ophthalmologica. 2019;242:123–162. doi:10.1159/000502041
  • Singer MA, Dugel PU, Fine HF, Capone JA, Maltman J. Real-world assessment of dexamethasone intravitreal implant in DME: findings of the prospective, multicenter REINFORCE study. Ophthalmic Surg Lasers Imaging Retina. 2018;49:425–435. doi:10.3928/23258160-20180601-07
  • Castro-Navarro V, Cervera-Taulet E, Navarro-Palop C, et al. Intravitreal dexamethasone implant Ozurdex® in naïve and refractory patients with different subtypes of diabetic macular edema. BMC Ophthalmol. 2019;19:15. doi:10.1186/s12886-018-1022-9
  • Ming S, Xie K, Yang M, et al. Comparison of intravitreal dexamethasone implant and anti-VEGF drugs in the treatment of retinal vein occlusion-induced oedema: a meta-analysis and systematic review. BMJ Open. 2020;10:e032128. doi:10.1136/bmjopen-2019-032128
  • Rosenblatt A, Udaondo P, Cunha-Vaz J, et al. A collaborative retrospective study on the efficacy and safety of intravitreal dexamethasone implant (Ozurdex) in patients with diabetic macular edema: the European DME registry study. Ophthalmology. 2020;127:377–393. doi:10.1016/j.ophtha.2019.10.005
  • Augustin AJ, Becker MD, Hatz K, Kaymak H, Shirlaw A. Assessment of reinjection numbers and intervals for diabetic macular edema patients who received dexamethasone intravitreal implants in Germany and Switzerland. Clin Ophthalmol. 2021;15:3957–3967. doi:10.2147/OPTH.S315548
  • Gale R, Gill C, Pikoula M, et al. Multicentre study of 4626 patients assesses the effectiveness, safety and burden of two categories of treatments for central retinal vein occlusion: intravitreal anti-vascular endothelial growth factor injections and intravitreal Ozurdex injections. Br J Ophthalmol. 2021;105:1571–1576. doi:10.1136/bjophthalmol-2020-317306
  • Kim MS, Choi J, Lee HD, Woo SJ. Dexamethasone intravitreal implant for the treatment of macular edema following retinal vein occlusion: post hoc analysis of post-marketing surveillance data in the real-world setting in Korea. Clin Ophthalmol. 2021;15:3623–3636. doi:10.2147/OPTH.S302014
  • Neves P, Ornelas M, Matias I, et al. Dexamethasone intravitreal implant (Ozurdex) in diabetic macular edema: real-world data versus clinical trials outcomes. Int J Ophthalmol. 2021;14:1571–1580. doi:10.18240/ijo.2021.10.15
  • Bhandari S, Gabrielle PH, Nguyen V, et al. Dexamethasone implant for diabetic macular oedema: 1-year treatment outcomes from the fight retinal blindness! Registry. Ophthalmol Ther. 2022;11:797–810. doi:10.1007/s40123-022-00473-3
  • Chang-Lin JE, Attar M, Acheampong AA, et al. Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci. 2011;52:80–86. doi:10.1167/iovs.10-5285
  • Gedde SJ, Vinod K, Wright MM, et al. Primary open-angle glaucoma preferred practice pattern. Ophthalmology. 2021;128:71–P150.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.